| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | nuclear phosphoprotein p21/SIIR; p21; pp21; TCAL1; TCEAL1 |
| Entrez GeneID | 9338; |
| WB Predicted band size | 20kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from internal of human TCEAL1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于TCEAL1抗体的模拟参考文献示例(基于公开研究主题模拟，非真实文献)：
---
1. **文献名称**：*TCEAL1 modulates ovarian cancer cell proliferation via Wnt/β-catenin signaling*
**作者**：Chen L, et al.
**摘要**：本研究通过Western blot和免疫组化实验，使用TCEAL1特异性抗体证实其在卵巢癌组织中表达下调。功能实验表明，TCEAL1通过抑制Wnt/β-catenin通路调控癌细胞增殖，提示其作为肿瘤抑制因子的潜在作用。
---
2. **文献名称**：*Proteomic identification of TCEAL1-interacting proteins in breast cancer*
**作者**：Kim S, et al.
**摘要**：利用TCEAL1抗体进行免疫共沉淀(Co-IP)结合质谱分析，鉴定出TCEAL1与核糖体蛋白RPL11和转录因子c-Myc的相互作用，揭示其在乳腺癌中调控蛋白质合成与细胞周期的新机制。
---
3. **文献名称**：*TCEAL1 as a biomarker for chemoresistance in colorectal cancer*
**作者**：Wang Y, et al.
**摘要**：通过免疫荧光和流式细胞术，采用TCEAL1抗体检测结直肠癌患者组织样本，发现高表达TCEAL1与5-FU化疗耐药显著相关，机制涉及p53通路失活，提示其可作为耐药预测标志物。
---
注：以上文献为示例，实际引用时需查询真实数据库(如PubMed)获取准确信息。
**Background of TCEAL1 Antibody**
TCEAL1 (Transcription Elongation Factor A Like 1) is a member of the TCEAL family, which comprises nuclear proteins implicated in modulating transcriptional regulation, chromatin remodeling, and cellular differentiation. TCEAL1 is encoded by a gene located on the X chromosome (Xq22.1) and is broadly expressed in human tissues, with higher levels observed in the ovary, brain, and immune cells. Functionally, TCEAL1 is suggested to act as a transcriptional regulator, potentially influencing pathways related to cell cycle progression, apoptosis, and oncogenesis. Its role in cancer is of particular interest, as aberrant expression of TCEAL1 has been linked to tumor suppression or promotion in context-dependent manners, notably in ovarian, breast, and prostate cancers.
Antibodies targeting TCEAL1 are essential tools for investigating its expression, localization, and interactions in both physiological and pathological contexts. These antibodies are commonly validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Researchers utilize TCEAL1 antibodies to explore its potential as a biomarker or therapeutic target, especially in cancers where its dysregulation correlates with disease progression or treatment resistance. However, challenges remain in fully elucidating its mechanistic roles, necessitating rigorous validation of antibody specificity to avoid cross-reactivity with other TCEAL family members. Studies employing TCEAL1 antibodies continue to shed light on its involvement in cellular stress responses and epigenetic regulation, underscoring its biological significance.
×
